Literature DB >> 11981754

Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.

Gianfranco Alpini1, Leonardo Baiocchi, Shannon Glaser, Yoshiyuki Ueno, Marco Marzioni, Heather Francis, Jo Lynne Phinizy, Mario Angelico, Gene Lesage.   

Abstract

Accumulating bile acids (BA) trigger cholangiocyte proliferation in chronic cholestasis. The aim of this study was to determine if ursodeoxycholate (UDCA) or tauroursodeoxycholate (TUDCA) chronic feeding prevents the increased cholangiocyte growth and secretion in bile duct-ligated (BDL) rats, if UDCA and TUDCA effects are associated with increased cholangiocyte apoptosis, and to determine if this inhibition is dependent on increased intracellular Ca(2+) ([Ca(2+)](i)) and activation of protein kinase C (PKC) alpha. Immediately after BDL, rats were fed UDCA or TUDCA (both 275 micromol/d) for 1 week. We determined the number of bile ducts in liver sections, cholangiocyte proliferation (by measurement of H(3) histone and proliferating cellular nuclear antigen in isolated cholangiocytes), and ductal secretion. In purified cholangiocytes from 1-week BDL rats, we evaluated if UDCA and TUDCA directly inhibit cholangiocyte proliferation and secretin-stimulated adenosine 3', 5'-monophosphate levels. We determined if UDCA and TUDCA activate PKC, increase [Ca(2+)](i), and alter the apical BA transporter (ABAT) expression in cholangiocytes. UDCA and TUDCA inhibited in vivo the cholangiocyte proliferation, secretion, and ABAT expression. In vitro UDCA and TUDCA inhibition of cholangiocyte growth and secretion required increased [Ca(2+)](i) and PKC alpha. In conclusion, activation of Ca(2+)-dependent PKC alpha is required for UDCA and TUDCA inhibition of cholangiocyte growth and secretion. Reduced cholangiocyte ABAT may decrease endogenous BA stimulation of cholangiocyte growth and secretion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981754     DOI: 10.1053/jhep.2002.32712

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

1.  Use of medaka in toxicity testing.

Authors:  Stephanie Padilla; John Cowden; David E Hinton; Bonny Yuen; Sheran Law; Seth W Kullman; Rodney Johnson; Ronald C Hardman; Kevin Flynn; Doris W T Au
Journal:  Curr Protoc Toxicol       Date:  2009-02

2.  Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP3/Ca2+ and cAMP-dependent signaling mechanisms.

Authors:  Heather L Francis; Sharon Demorrow; Antonio Franchitto; Julie K Venter; Romina A Mancinelli; Mellanie A White; Fanyin Meng; Yoshiyuki Ueno; Guido Carpino; Anastasia Renzi; Kimberly K Baker; Hannah E Shine; Taylor C Francis; Eugenio Gaudio; Gianfranco D Alpini; Paolo Onori
Journal:  Lab Invest       Date:  2011-11-07       Impact factor: 5.662

3.  Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts.

Authors:  Marco Marzioni; Heather Francis; Antonio Benedetti; Yoshiyuki Ueno; Giammarco Fava; Juliet Venter; Ramona Reichenbach; Maria Grazia Mancino; Ryun Summers; Gianfranco Alpini; Shannon Glaser
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 4.  Physiology of cholangiocytes.

Authors:  James H Tabibian; Anatoliy I Masyuk; Tetyana V Masyuk; Steven P O'Hara; Nicholas F LaRusso
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

5.  Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Authors:  Patricia Munoz-Garrido; José J G Marin; María J Perugorria; Aura D Urribarri; Oihane Erice; Elena Sáez; Miriam Úriz; Sarai Sarvide; Ainhoa Portu; Axel R Concepcion; Marta R Romero; María J Monte; Álvaro Santos-Laso; Elizabeth Hijona; Raúl Jimenez-Agüero; Marco Marzioni; Ulrich Beuers; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Joost P H Drenth; Jesús M Banales
Journal:  J Hepatol       Date:  2015-06-01       Impact factor: 25.083

Review 6.  Cholangiocyte proliferation and liver fibrosis.

Authors:  Shannon S Glaser; Eugenio Gaudio; Tim Miller; Domenico Alvaro; Gianfranco Alpini
Journal:  Expert Rev Mol Med       Date:  2009-02-25       Impact factor: 5.600

7.  Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression.

Authors:  Romina Mancinelli; Paolo Onori; Eugenio Gaudio; Antonio Franchitto; Guido Carpino; Yoshiyuki Ueno; Domenico Alvaro; Luigi P Annarale; Sharon Demorrow; Heather Francis
Journal:  Exp Biol Med (Maywood)       Date:  2009-02-20

8.  Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis.

Authors:  Kazunori Shibao; Keiji Hirata; Marie E Robert; Michael H Nathanson
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

9.  Ursodeoxycholate further increases bile-duct cell proliferative response induced by partial bile-duct ligation in rats.

Authors:  Michele Barone; Eugenio Maiorano; Roberta Ladisa; Antonia Pece; Pasquale Berloco; Mario Strazzabosco; Maria Lucia Caruso; Anna Maria Valentini; Enzo Ierardi; Alfredo Di Leo; Antonio Francavilla
Journal:  Virchows Arch       Date:  2004-04-08       Impact factor: 4.064

10.  Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis.

Authors:  M Marzioni; G Alpini; S Saccomanno; C Candelaresi; J Venter; C Rychlicki; G Fava; H Francis; L Trozzi; A Benedetti
Journal:  Gut       Date:  2008-10-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.